A Double Blind, Randomized, Placebo Controlled, Dose Escalation Phase 2a Clinical Trial for the Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2018
At a glance
- Drugs RZL-012 (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Raziel Therapeutics
- 01 Sep 2018 Planned End Date changed from 1 Jul 2018 to 1 Jan 2019.
- 01 Sep 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jan 2019.
- 01 Sep 2018 Status changed from recruiting to active, no longer recruiting.